News Center

位置：

Honors Announcement

Group News

Media Reports

Shijiazhuang Sihua Pharmaceutical’s “Shimen” brand has been awarded the title of China’s Consumer Brand of the Year 2025.

Category:

Group News

发布时间：2026-02-04

【概要描述】 Recently, the Ministry of Industry and Information Technology officially released the 2025 List of China’s Famous Consumer Brands. Shijiazhuang Sihua Pharmaceutical Co., Ltd.’s “Shimen” brand was successfully selected as a 2025 China Famous Consumer Brand (Timeless Excellence) thanks to its outstanding product quality, continuous innovation capabilities, and impressive market performance. This honor not only represents high recognition of the company’s overall strength but also underscores its exemplary and leading role in promoting the high-quality development of the consumer goods industry, while simultaneously bringing prestigious recognition to Shijiazhuang’s biopharmaceutical sector.

Recently, the Ministry of Industry and Information Technology officially released the 2025 List of China’s Famous Consumer Brands. Shijiazhuang Sihua Pharmaceutical Co., Ltd.’s “Shimen” brand was successfully selected as a 2025 China Famous Consumer Brand (Timeless Excellence) thanks to its outstanding product quality, continuous innovation capabilities, and impressive market performance. This honor not only represents high recognition of the company’s overall strength but also underscores its exemplary and leading role in promoting the high-quality development of the consumer goods industry, while simultaneously bringing prestigious recognition to Shijiazhuang’s biopharmaceutical sector.

According to reports, the China Consumer Excellence Selection Initiative focuses on national strategic priorities and the public’s aspiration for a better life. Adhering to the principles of “self-nomination, selection of the best from among the excellent, and dynamic management,” the initiative solicits high-quality corporate and regional brands across three dimensions: time-honored classics, contemporary premium products, and cutting-edge trendsetters. The call is primarily directed toward consumer goods sectors such as light industry, textiles, food, and pharmaceuticals, with a particular emphasis on supporting product brands tailored to specific demographic groups—including age-friendly products, assistive devices for persons with disabilities, and products for women and children. The initiative aims to strengthen coordination between central and local authorities in promoting and marketing China’s consumer excellence brands, accelerate the establishment of a China-specific consumer excellence system centered on corporate and regional brands, and thereby bolster the high-quality development of the consumer goods industry.

As a pillar enterprise in Shijiazhuang’s biopharmaceutical industry, Shijiazhuang Sihua Pharmaceutical has remained true to its original mission of “producing high-quality medicines for the people.” From its humble beginnings in the manufacture of sanitary materials and large-volume parenterals to its current successful transformation into an integrated API–formulation business, the company has consistently upheld innovation and quality as the cornerstones of the “Shimen” brand. Over the years, the “Shimen” brand has steadily evolved, showcasing a timeless appeal that blends heritage with innovation, and has earned a well-deserved reputation among consumers as an outstanding brand. It has been recognized as an Excellent Brand and a Renowned Brand of Hebei Province, as well as a Time-Honored Brand of both Hebei Province and Shijiazhuang, further solidifying its rich brand legacy and cultural depth.

In recent years, in particular, Shijiazhuang Sihua Pharmaceutical has positioned innovation as the core driving force behind the development of new-quality productive forces. Closely aligned with national development strategies and market demands, the company has accelerated the integrated development of active pharmaceutical ingredients and finished dosage forms, continuously increased R&D investment, and optimized its innovation ecosystem. Proactively responding to national policy orientations such as age-friendly and child-friendly initiatives, the company has expedited the development of new products tailored to specific population groups, thereby consistently supporting the Healthy China initiative. Notably, Shijiazhuang Sihua Pharmaceutical has successfully researched and developed stiripentol dry suspension for the treatment of severe myoclonic epilepsy in infants—a rare disease known as Dravet syndrome. Following national medical insurance negotiations, this product was included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2024) in November 2024, providing a new, more cost-effective treatment option for affected children.

Innovation has driven the continuous expansion of the company’s product portfolio. To date, Shijiazhuang Sihua Pharmaceutical has had a cumulative total of 168 generic drug varieties and 220 specifications that have passed the consistency evaluation, maintaining a leading position in the industry. Leveraging this achievement, the company has actively utilized national and local centralized bulk procurement and other market-access platforms, deeply engaging in the development of a unified national market and significantly enhancing the accessibility of “Shimen”-branded products. These products are now distributed across the country and exported to more than 100 countries and regions. At present, Shijiazhuang Sihua Pharmaceutical has preliminarily established a modern industrial system characterized by innovative drugs as the driving force, specialty chemical formulations and active pharmaceutical ingredients as the core, and high-end pharmaceutical packaging materials and specialized biologics as extensions, with steadily strengthening resilience and vitality.

The head of Shijiazhuang No. 4 Pharmaceutical stated, “The successful inclusion of the company’s ‘Shimen’ brand not only underscores its profound influence in the pharmaceutical market but also paves the way for innovative approaches to high-quality corporate development. Moving forward, the company will remain innovation-driven and quality-focused, further strengthening the formulation and development of age-friendly and pediatric-specific products. We are committed to providing consumers with more high-quality medicines, continuously enhancing the ‘Good Chinese Medicines—Made in Shijiazhuang’ brand, and making a greater contribution to the Healthy China initiative and the growth of Shijiazhuang’s biopharmaceutical industry.”

Keywords:

Shijiazhuang Sihua Pharmaceutical Group Holds Press Conference on Its 2026 R&D and Innovation Goals

A Skilled Professional at Shijiazhuang Sihua Pharmaceutical Group Awarded the Title of “Top Talent under the Hebei Province Yanzhao Golden Platform Talent Attraction Program”

Shijiazhuang Sihua Pharmaceutical Group Holds Press Conference on Its 2026 R&D and Innovation Goals

A Skilled Professional at Shijiazhuang Sihua Pharmaceutical Group Awarded the Title of “Top Talent under the Hebei Province Yanzhao Golden Platform Talent Attraction Program”